Taro Provides Results for Quarter Ended June 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
UPDATE: Taro Pharma (TARO) Reports Q1 EPS of $2.59
August 10, 2016 5:13 PM EDT(Updated - August 10, 2016 5:14 PM EDT)
(Updated to reflect Q1 results, not Q4)
Taro Pharma (NYSE: TARO) reported Q1 EPS of $2.59, versus $2.42 reported last year. Revenue for the quarter came in at $233.8 million, versus $215.3 million reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
... More